Analysts Anticipate Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.41 Per Share
Analysts predict that Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) will post ($1.41) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Alder BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.97) and the highest estimate coming in at ($1.12). Alder BioPharmaceuticals posted earnings per share of ($0.70) in the same quarter last year, which would indicate a negative year over year growth rate of 101.4%. The company is scheduled to issue its next quarterly earnings results on Thursday, October 26th.
According to Zacks, analysts expect that Alder BioPharmaceuticals will report full-year earnings of ($6.35) per share for the current financial year, with EPS estimates ranging from ($7.91) to ($5.40). For the next fiscal year, analysts forecast that the business will report earnings of ($4.35) per share, with EPS estimates ranging from ($6.84) to ($3.56). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Alder BioPharmaceuticals.
Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.67) by $0.19. The company had revenue of $0.68 million for the quarter. During the same period in the previous year, the company earned ($0.79) earnings per share. The firm’s revenue for the quarter was up 518.2% on a year-over-year basis.
A number of equities research analysts have issued reports on ALDR shares. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, July 11th. Credit Suisse Group lowered shares of Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $30.00 to $17.00 in a report on Wednesday, June 28th. Needham & Company LLC assumed coverage on shares of Alder BioPharmaceuticals in a report on Monday, May 15th. They issued a “buy” rating and a $36.00 price objective for the company. Wells Fargo & Company reiterated an “outperform” rating and issued a $51.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, June 28th. Finally, ValuEngine lowered shares of Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, June 29th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $33.75.
In other news, Director Stephen M. Dow purchased 25,000 shares of the stock in a transaction on Tuesday, July 18th. The stock was purchased at an average price of $10.00 per share, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.60% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALDR. Sei Investments Co. raised its position in Alder BioPharmaceuticals by 2,297.8% in the first quarter. Sei Investments Co. now owns 25,584 shares of the biopharmaceutical company’s stock valued at $532,000 after buying an additional 24,517 shares during the last quarter. Swiss National Bank raised its position in Alder BioPharmaceuticals by 2.6% in the first quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock valued at $1,380,000 after buying an additional 1,700 shares during the last quarter. Pictet Asset Management Ltd. raised its position in Alder BioPharmaceuticals by 69.7% in the first quarter. Pictet Asset Management Ltd. now owns 611,706 shares of the biopharmaceutical company’s stock valued at $12,724,000 after buying an additional 251,249 shares during the last quarter. Bank of New York Mellon Corp raised its position in Alder BioPharmaceuticals by 4.6% in the first quarter. Bank of New York Mellon Corp now owns 210,401 shares of the biopharmaceutical company’s stock valued at $4,377,000 after buying an additional 9,218 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Alder BioPharmaceuticals by 5.7% in the first quarter. American Century Companies Inc. now owns 70,486 shares of the biopharmaceutical company’s stock valued at $1,466,000 after buying an additional 3,815 shares during the last quarter. Hedge funds and other institutional investors own 82.44% of the company’s stock.
Shares of Alder BioPharmaceuticals (ALDR) traded up 4.89% during mid-day trading on Wednesday, hitting $9.65. 1,388,777 shares of the stock traded hands. The company’s market cap is $486.46 million. Alder BioPharmaceuticals has a 52 week low of $9.40 and a 52 week high of $36.48. The stock has a 50-day moving average of $12.91 and a 200-day moving average of $18.65.
ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Alder BioPharmaceuticals, Inc. (ALDR) Will Post Earnings of -$1.41 Per Share” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/19/analysts-anticipate-alder-biopharmaceuticals-inc-aldr-will-post-earnings-of-1-41-per-share-updated.html.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.